TruScreen Group (ASX:TRU, NZE:TRU) said that a July 2024 Saudi Arabia study investigating the TruScreen cervical screening technology's performance versus pap smears in cervical cancer detection was peer reviewed and published by the BMC Women's Health journal, according to bourse filings in Australia and New Zealand on Thursday.
The study tested 507 women and reported that Truscreen demonstrated a high sensitivity of 83.3%, compared to 66.7% from pap smears, and a high specificity of 95%, compared with 98.2% from pap smears, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。